Healthy AgeingNCT07528469
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
A study testing PeptiStrong + whey protein and Whey protein in people with Healthy Ageing and Protein Supplementation, run by Nuritas Ltd at 1 site in United Kingdom.
Trial summary
Examining the effects of PeptiStrong and protein on muscle function in older adults Read more about this study
- Who is it for?
- Ages 60 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Ageing, Protein Supplementation, Muscle Health
- What is being tested?
- PeptiStrong + whey protein and Whey protein
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 81 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Apr 2026to 30 Oct 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women aged 60 to 85 years at the time of enrolment
- Community-dwelling (living independently or with minimal assistance)
- Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)
- Willing and able to attend two study visits at the research facility (baseline and end of study)
- Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days
- Able to understand the study information and provide written informed consent
Who cannot join
- Any known food allergy or intolerance to fava bean protein or milk protein
- Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated
- Yes to any of the answers on the "Older Adult Functional Assessment Screening Questionnaire"
- Individuals with implanted electronic devices
- Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention
- Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults
Examining the effects of PeptiStrong and protein on muscle function in older adults
Read the detailed description
The aim of this study is to compare two protein drinks containing whey protein (derived from milk) in healthy adults aged 60 to 85 years. One group will consume a standard whey protein drink (20g), while the other group will consume a drink with half the total protein dose (10g) made of whey protein and PeptiStrong, a fava bean hydrolysate containing bioactive peptides.
The study will assess whether the lower protein drink containing PeptiStrong will lead to equal or greater improvements than the standard drink in physical function, such as the ability to stand up from a chair, walk at a normal pace, maintain balance, and grip strength. The study will also examine markers related to inflammation, fatigue, and quality of life.
The intended value of this research is to improve understanding of how targeted nutritional strategies may help maintain or improve muscle function in older adults. The findings may help inform future nutritional recommendations and the development of practical dietary interventions aimed at supporting healthy ageing and independence.
- Conditions
- Healthy Ageing, Protein Supplementation, Muscle Health, Muscle Function, Hand Grip Strength, Longevity
- Being tested
- PeptiStrong + whey protein, Whey protein
- Keywords
- Healthy Aging, Protein supplementation, Muscle function, Physical performance, Longevity, Bioactive peptides, Hand grip strength, Short performance physical battery, Nuritas, Liverpool John Moore University
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PeptiStrong + whey proteinDietary supplement
Fava bean protein hydrolysate containing bioactive peptides mixed with whey protein as dry powder for drinkable protein shake
Whey proteinDietary supplement
Whey protein as dry powder for drinkable protein shake
| Study group | Role | What they receive |
|---|---|---|
| PeptiStrong + whey protein | Experimental | 2.4g PeptiStrong (provides 1.6g protein) + 8.4g of whey protein = 10g total protein Receives: Dietary Supplement: PeptiStrong + whey protein |
| Whey protein | Active comparator | 20g whey protein Receives: Dietary Supplement: Whey protein |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hand Grip Strength via hand held dynamometer
Change from baseline to end of study in grip strength as assessed via hand held dynamometer
Measured: Baseline to Week 4
Secondary outcomes (10)
Chair Stand Test - Part of short performance physical battery
Change from baseline to end of study in physical function assessment via chair stands. This test measures the time taken to complete 5 sit-to-stand repetitions in seconds. A lower time (fewer seconds) = better performance. As part of the full short performance physical battery it is converted to a subscore of 0-4, where a higher score = better performance
Measured: Baseline to week 4
Gait Speed as part of short performance physical battery
Change from baseline to end of study in physical function assessment assessed as time to walk a fixed distance in seconds and reporting in meters per second. Higher speeds indicate better performance. This is converted to a subscore of 0-4 within the full short performance physical battery
Measured: Baseline to week 4
6 Minute Walking Endurance Test
Change from baseline to end of study in physical function and endurance assessed as the total distance walked in 6 minutes in meters. A greater distance reflects better walking endurance and functional capacity.
Measured: Baseline to week 4
Balance test as part of short performance physical battery
Change from baseline to end of study in balance as assessed by the ability to hold three standing positions of increasing difficulty: side-by-side, semi-tandem, and tandem stance in seconds. Higher scores indicate better balance. The overall score is converted to a a sub-score of 0-4 within the full short performance physical battery.
Measured: Baseline to week 4
Balance assessment via force plates
Change from baseline to end of study in balance as assessed via force plates
Measured: Baseline to week 4
Quality of Life via the Sarcopenia Quality of Life (SarQoL®) Questionnaire
Change from baseline to end of study in quality of life as measured via subjective SarQOL questionnaire. The total score ranges from 0 to 100, with higher scores reflecting a higher quality of life.
Measured: Baseline to week 4
Fatigue via Multidimensional Fatigue Inventory Questionnaire
Change from baseline to end of study in self-reported fatigue as assessed via multidimensional fatigue inventory questionnaire. This 20-item questionnaire covers five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity. Each subscale score ranges from 4 to 20, with higher scores indicating greater fatigue
Measured: Baseline to week 4
C-reactive protein (CRP) via blood test
Change from baseline to the end of study in inflammatory marker C-reactive protein (CRP) in serum as mg/L
Measured: Baseline to week 4
Interleukins via blood test
Change from baseline to the end of study in Interleukin inflammatory markers in serum as pg/mL
Measured: Baseline to week 4
Body composition: Muscle mass and body fat via bioelectrical impedance analysis
Change from baseline to end of study in muscle mass and body fat as measured by bioelectrical impedance analysis in kilograms and % of total body weight
Measured: Baseline to week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study start6 Apr 2026
- Primary completion30 Jul 2026
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy AgeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Non-randomised, quadruple-blind, active-comparator, parallel study conducted over 4 weeks
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 81 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nuritas Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Liverpool John Moores University
- Responsible party
- Sponsor
- Investigators
- Graeme Close, Professor, Principal investigator, Liverpool John Moore University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07528469
- Sponsor's protocol ID
- PEPVFH+60/26
- Status last verified
- Sep 2026
- First submitted
- 30 Mar 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No